CLEVELAND, Ohio — Athersys, Inc. , a leader in the emerging field of regenerative medicine, announced today grant funding aggregating $3.6 million to further advance its MultiStem(R) product programs …

The rest is here:
Athersys Awarded $3.6 Million in Grant Funding for Stem Cell Product Development

Advanced Cell Technology, Inc.

Read the original here:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …

Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic stem cell -derived retinal pigment epithelium cells for the treatment of Stargardt’s macular dystrophy and dry age-related macular degeneration .

Read more here:
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

WESTON, Fla.

Visit link:
Stemlogix Significantly Expands Its Stem Cell Therapy Options to Veterinarians and Their Patients

CAMBRIDGE, MA– – Radius Health, Inc. announced today positive results from a Phase 1b clinical study to evaluate the transdermal BA058 Microneedle Patch

See the original post:
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal …

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual …

View post:
EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Advanced Cell Technology, Inc.

See the original post:
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec

Link:
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesas Investor and Partnering Forum

Zosano Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) announced today that they have entered into a long-term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of TeriboneT (teriparatide acetate), AKP’s formulation of human parathyroid hormone (human PTH 1-34), for the treatment of osteoporosis patients with a high …

See the original post:
Zosano Pharma, Inc. And Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement For A Weekly Transdermal …

Advanced Cell Technology, Inc. ;, a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium derived from human embryonic stem cells .

Read the rest here:
ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe